Evidence map›Paper›PMID 40184324›Full record

ArticleImmunotherapy2025

Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data.

Courtney H Coschi, Keyue Ding, Justin Tong, Dongsheng Tu, Christopher O'Callaghan, Natasha B Leighl, Francisco Vera-Badillo, Rosalyn A Juergens, Desiree Hao, Lesley Seymour and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Medical Cannabis and the Hallmarks of Cancer: A Critical Narrative Review.International journal of molecular sciences · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Courtney H CoschiCanadian Cancer Trials Group, Kingston, ON, Canada.
Keyue DingCanadian Cancer Trials Group, Kingston, ON, Canada.
Justin TongKingston Health Sciences Centre, Kingston, ON, Canada.
Dongsheng TuCanadian Cancer Trials Group, Kingston, ON, Canada.
Christopher O'CallaghanCanadian Cancer Trials Group, Kingston, ON, Canada.
Natasha B LeighlUniversity Health Network, Toronto, ON, Canada.
Francisco Vera-BadilloCancer Centre of Southeastern Ontario, Kingston, ON, Canada.
Rosalyn A JuergensJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Desiree HaoArthur J.E. Child Comprehensive Cancer Centre and Cumming School of Medicine, Calgary, AB, Canada.
Lesley SeymourCanadian Cancer Trials Group, Kingston, ON, Canada.
Daniel J RenoufPancreas Centre, BC Cancer, Vancouver, BC, Canada.
Eric ChenPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Pierre-Olivier GaudreauCanadian Cancer Trials Group, Kingston, ON, Canada.
Andrea S FungArthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) benefit patients across various tumor types. ICIs block cancer and T-cell interactions whereas cannabinoids may inhibit T-cell activation, reducing lysis of tumor cells. Interactions between cannabinoid use and dual ICI treatment remain unknown.

methodsIndividual patient data from 4 Canadian Cancer Trials Group (CCTG) trials of patients treated with dual ICI ± chemotherapy (

resultsSixty-five (9.5%) patients took cannabinoids at any time on trial, 32 (4.7%) of which were using cannabinoids at baseline. By multivariate analysis, cannabinoid use at baseline was significantly associated with improved iPFS (0.05), but not iBOR (

conclusionImproved iPFS with cannabinoid use in patients treated with durvalumab plus tremelimumab ± chemotherapy did not translate into OS benefits. This study supports the safe use of cannabinoids in the context of combination ICI therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCannabinoidsImmune Checkpoint InhibitorsNeoplasmsAdultAgedCanadaFemaleHumansMaleMiddle AgedTreatment OutcomeCannabinoidsImmune Checkpoint InhibitorsAnti-CTLA-4Anti-PD-1Anti-PD-L1cannabinoidsdurvalumabimmune checkpoint inhibitorsImmunotherapytremelimumab

Identifiers

PMID40184324
PMCPMC12036482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.